Overview

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.
Phase:
Phase 2
Details
Lead Sponsor:
Theravance Biopharma
Theravance Biopharma R & D, Inc.
Treatments:
Analgesics, Opioid